Growth Hormone Replacement Therapy for Retried Professional Football Players

Description

This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).

Conditions

TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).

Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency

Growth Hormone Replacement Therapy for Retried Professional Football Players

Condition
TBI (Traumatic Brain Injury)
Intervention / Treatment

-

Contacts and Locations

Dearborn

Center for Neurolgoical Studies (CNS), Dearborn, Michigan, United States, 48126

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * The subject is willing to provide a signed and dated informed consent indicating that he understands the purpose and procedures required for the study and is willing to participate in the study.
  • * Former NFL player
  • * At least one year since retirement from football
  • * Less than 76 years of age
  • * Diagnosis of GHD on clinical grounds by a neurologist and an endocrinologist GHD
  • * History of pre-existing brain disease other than concussion or TBI
  • * History of a premorbid disabling condition that interferes with outcome assessments
  • * Contraindication to GH therapy
  • * Type I and II Diabetes mellitus
  • * Active malignant disease
  • * Acute critical illness, heart failure, or acute respiratory failure
  • * Subjects who are deficient in cortisol, testosterone or thyroid at screening will be excluded until hormone abnormalities have been corrected.

Ages Eligible for Study

18 Years to 76 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Center for Neurological Studies,

Randall R Benson, MD, PRINCIPAL_INVESTIGATOR, Vice President and Medical Director

Study Record Dates

2026-09